May 29, 2020
Otsuka Holdings’ pharmaceutical revenue in the first quarter of 2020 grew over 13%, driven by four global brands including the selective vasopressin V2 receptor antagonist tolvaptan and the antipsychotic Abilify Maintena (aripiprazole), according to its earnings released on May 28...read more